News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/images/articles/hemtimes/ht-logo-end.gif)
CNS involvement doesn’t affect survival after allo-SCT
- Author:
- Jen Smith
By analyzing transplant outcomes in more than 5000 patients, researchers found that subjects with CNS AML had rates of relapse and survival that...
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/images/articles/hemtimes/ht-logo-end.gif)
Bacteria may protect against GVHD-related mortality
- Author:
- Jen Smith
Experiments showed that Blautia, commensal bacteria found in the intestinal tract, can protect against GVHD-related mortality in mice and in...
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/images/articles/hemtimes/ht-logo-end.gif)
TNC dose can affect PFS, OS after PBSCT
- Author:
- Jen Smith
Researchers found that a higher TNC dose was associated with better progression-free survival (PFS) and overall survival (OS) among patients who...
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/images/articles/hemtimes/ht-logo-end.gif)
Allo-SCT can be effective in advanced SS, MF
- Author:
- Jen Smith
Allogeneic stem cell transplant (SCT) proved particularly effective in patients with Sézary syndrome (SS). It also conferred benefits to mycosis...
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/images/articles/hemtimes/ht-logo-end.gif)
Consortium study falls short of expectations
- Author:
- Jen Smith
The North American PTCL Consortium set out to find a treatment that could best CHOP (cyclophosphamide, hydroxydaunorubicin, vincristine, and...
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/images/articles/hemtimes/ht-logo-end.gif)
Regimen shows promise for ENKTL
- Author:
- Jen Smith
The combination of pegaspargase, gemcitabine, and oxaliplatin (P-Gemox) elicited a high rate of response in this cohort of 60 Chinese patients. P...
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/images/articles/hemtimes/ht-logo-end.gif)
TNFRII may play key role in CTCL, speaker says
- Author:
- Jen Smith
The team discovered that a mutation in this receptor—TNFRII T377I—is present in patients with mycosis fungoides (MF) and those with Sézary...
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/images/articles/hemtimes/ht-logo-end.gif)
Inhibitor appears active in relapsed/refractory TCLs
- Author:
- Jen Smith
Among 26 evaluable patients, 9 experienced partial responses to treatment with IPI-145, and 1 achieved a complete response, for an overall...
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/images/articles/hemtimes/ht-logo-end.gif)
A new prognostic model for PTCL?
- Author:
- Jen Smith
Researchers analyzed nearly 9000 patients diagnosed with PTCL in the US and found evidence to suggest that patient age and race, as well as...
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/images/articles/hemtimes/Younes_Anas_240.jpg)
Is the US running too many T-cell lymphoma trials?
- Author:
- Jen Smith
SAN FRANCISCO—The US currently has 284 open clinical trials enrolling patients with T-cell lymphomas, a fact that is actually detrimental to this...
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/images/articles/hemtimes/ico_ht.gif)
CTAs are promising therapeutic targets in MM
- Author:
- Jen Smith